(Q50169188)

26 February 2018

title

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. (English)

1 reference

26 February 2018

author name string

Sadahisa Ogasawara

1

1 reference

26 February 2018

Tetsuhiro Chiba

2

1 reference

26 February 2018

Yoshihiko Ooka

3

1 reference

26 February 2018

Eiichiro Suzuki

4

1 reference

26 February 2018

Takahiro Maeda

5

1 reference

26 February 2018

Masayuki Yokoyama

6

1 reference

26 February 2018

Toru Wakamatsu

7

1 reference

26 February 2018

Masanori Inoue

8

1 reference

26 February 2018

Tomoko Saito

9

1 reference

26 February 2018

Kazufumi Kobayashi

10

1 reference

26 February 2018

Soichiro Kiyono

11

1 reference

26 February 2018

Masato Nakamura

12

1 reference

26 February 2018

Shingo Nakamoto

13

1 reference

26 February 2018

Shin Yasui

14

1 reference

26 February 2018

Akinobu Tawada

15

1 reference

26 February 2018

Makoto Arai

16

1 reference

26 February 2018

Tatsuo Kanda

17

1 reference

26 February 2018

Hitoshi Maruyama

18

1 reference

26 February 2018

Osamu Yokosuka

19

1 reference

26 February 2018

Naoya Kato

20

1 reference

26 February 2018

publication date

11 September 2017

1 reference

26 February 2018

Investigational New Drugs

published in

1 reference

26 February 2018

https://scigraph.springernature.com/pub.10.1007/s10637-017-0507-3

exact match

0 references

cites work

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

The preclinical development of regorafenib for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0507-3

10.1007/S10637-017-0507-3

21 January 2018

Identifiers

DOI

1 reference

26 February 2018

1 reference

26 February 2018